Spain's Esteve names new CCO for Europe

15 February 2019

Spanish family-owned drugmaker Esteve has appointed Jordi Muntañola as the new chief commercial officer for Europe, taking on the leadership of all the pharmaceutical activities in Spain and Europe.

Dr Muntañola takes over from Joe Sullivan, who remains at the company for a few months to facilitate a smooth transition.

Dr Muntañola joined Esteve’s team in 2016 as director of pharma operational excellence, a responsibility to which, at a later stage, the management of the Consumer Care Division was added.

Dr Muntañola holds a PhD in Molecular Biology from the University of Navarra and an MBA from ESADE. He has broad experience in the healthcare sector at companies such as the Werfen Group and Esaote, among others. Throughout his career, Dr Muntañola has formed part of and managed teams of R&D, corporate strategy, business development, operations and business management, and has headed business transformation projects in Spain as well as internationally.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK